Lai: Mu Fengda's new indication approved by the China National Medical Products Administration.

Medication introduced by Lilly, Mu Feng Da, has been approved by the Chinese National Medical Products Administration for use in conjunction with insulin therapy to improve blood sugar control in adults with type 2 diabetes on a diet and exercise regimen.